Cadila Healthcare confirmed that Zydus Cadila has received the final nod from the USFDA to market Amitriptyline Hydrochloride Tablets USP in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg.
The drug is used to treat depression and will be manufactured at Cadila’s formulations manufacturing facility at SEZ, Ahmedabad.
A few days back, the company received final approval to market Fesoterodine Fumarate extended-release tablets used to treat an overactive bladder. The sales of these drugs are estimated at USD 195.5 mn.
The group has now more than 160 approvals and so far filed over 300 ANDAs since the commencement of the filing process in FY04.
Cadila Healthcare Ltd is currently trading at Rs 505.7, up by Rs 5.15 or 1.03% from its previous closing of Rs 500.55 on the BSE.